ADME-Tox studies

As you identify new candidate drugs for the potential treatment of COVID-19, you will need a reliable cell model to evaluate the absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) of your candidate drug. More accurate in vitro systems allow for more accurate in vivo predictions, which are critical for determining drug safety and efficacy in patients and advancing candidate drugs in the clinic.

We provide functional and mature iPS-derived hepatocytes and cardiomyocytes to evaluate your candidate drug's hepatotoxicity and cardiotoxicity. The iPS-derived hepatocytes can also be used to predict in vitro metabolism of a drug in the liver, the main site of drug metabolism in the body.

If you are working with primary hepatocytes, we offer our breakthrough Cellartis Power Primary HEP Medium, which allows long-term compound incubation so you can accurately measure the clearance rate of low-clearance compounds.

If you are developing an orally administered drug, our iPS-derived intestinal epithelial cells enable you to evaluate the metabolism and absorption of the drug by the small intestinal epithelium. These cells form tight junctions within five days of thawing and express drug-metabolizing enzymes and transporters at relevant levels.

With these tools, you can accurately predict how a drug will behave in vivo and increase the chances that your drug will succeed in clinical trials.